ceFAZolin, 2 G/20 mL in Sterile Water, 20 mL Sterile Syringe for Injection, IntegraDose Compoundi...
FDA Drug Recall #D-0896-2021 — Class II — September 17, 2021
Recall Summary
| Recall Number | D-0896-2021 |
| Classification | Class II — Moderate risk |
| Date Initiated | September 17, 2021 |
| Status | Terminated |
| Voluntary | Voluntary: Firm initiated |
Recalling Firm
| Firm | IntegraDose Compounding Services LLC |
| Location | Minneapolis, MN |
| Product Type | Drugs |
| Quantity | 2,614 syringes |
Product Description
ceFAZolin, 2 G/20 mL in Sterile Water, 20 mL Sterile Syringe for Injection, IntegraDose Compounding Services, LLC, 719 Kasota Ave SE, Minneapolis, MN. NDC 71139-7087-1
Reason for Recall
Lack of sterility assurance.
Distribution Pattern
NH, MA, MN
Lot / Code Information
Lot, expiry: Lot 20210803CEF-1, exp 09/17/2021; Lot 20210805CEF-3, 09/19/2021; Lots 20210806CEF-1, 20210806CEF-2, exp 09/20/2021; Lots 20210809CEF-1, 20210809CEF-2, exp 09/23/2021; Lot 20210810CEF-1, exp 09/24/2021; Lot 20210811CEF-1, exp 09/25/2021; Lot 20210812CEF-1, exp 09/26/2021
Other Recalls from IntegraDose Compounding Services LLC
| Recall # | Classification | Product | Date |
|---|---|---|---|
| D-0015-2026 | Class I | Oxytocin 30 Units/500 mL in 0.9% Sodium Chlorid... | Sep 16, 2025 |
| D-0432-2024 | Class II | fentaNYL Citrate 2,500 mcg/50mL in Sterile Wate... | Mar 22, 2024 |
| D-0325-2024 | Class II | Vasopressin 2 Units/2 mL in 0.9% Sodium Chlorid... | Jan 22, 2024 |
| D-0258-2024 | Class II | Vasopressin 2 Unit/2 mL in 0.9% Sodium Chloride... | Jan 12, 2024 |
| D-0897-2021 | Class II | ceFAZolin 3 G in 0.9% Sodium Chloride, 115 mL B... | Sep 17, 2021 |
Frequently Asked Questions
Injectable drugs and eye drops must be completely free of microbial contamination because they bypass the body's natural defenses. A contaminated injectable can introduce bacteria or fungi directly into the bloodstream, potentially causing sepsis, meningitis, or localized infections — all of which can be life-threatening. Contamination of sterile products almost always results in a Class I recall. If you received an injectable drug from a recalled lot, contact your healthcare provider immediately, even if you feel well, as some infections can have delayed onset.
Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications — even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.
Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.
What Should You Do?
Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications — use a drug take-back program.